NASDAQ:EDSA Edesa Biotech (EDSA) Stock Price, News & Analysis $6.03 +0.21 (+3.61%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$5.92 -0.11 (-1.77%) As of 07/21/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Edesa Biotech Stock (NASDAQ:EDSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edesa Biotech alerts:Sign Up Key Stats Today's Range$5.76▼$6.6050-Day Range$4.94▼$15.2452-Week Range$0.72▼$20.32Volume48,278 shsAverage Volume71,347 shsMarket Capitalization$58.09 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Edesa Biotech, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology. Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners. Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.AI Generated. May Contain Errors. Read More Edesa Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreEDSA MarketRank™: Edesa Biotech scored higher than 20% of companies evaluated by MarketBeat, and ranked 1513th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingEdesa Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Downside RiskEdesa Biotech has a consensus price target of $5.00, representing about 17.1% downside from its current price of $6.03.Amount of Analyst CoverageEdesa Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Edesa Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Edesa Biotech are expected to grow in the coming year, from ($1.66) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edesa Biotech is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edesa Biotech is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdesa Biotech has a P/B Ratio of 13.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edesa Biotech's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.89% of the float of Edesa Biotech has been sold short.Short Interest Ratio / Days to CoverEdesa Biotech has a short interest ratio ("days to cover") of 1.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edesa Biotech has recently decreased by 1.34%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdesa Biotech does not currently pay a dividend.Dividend GrowthEdesa Biotech does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for EDSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Edesa Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.50% of the stock of Edesa Biotech is held by institutions.Read more about Edesa Biotech's insider trading history. Receive EDSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDSA Stock News HeadlinesEDSA: Positive Exploratory Data in Patients with AKIJuly 2, 2026 | msn.comEdesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical ProgramsJune 11, 2026 | quiverquant.comQForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue growth in recorded history - from $1 billion in early 2025 to a projected $50 billion this year. Google, Amazon, Nvidia, and a fund backed by Peter Thiel have already taken positions. The Wall Street Journal projects $559 million in profit in a single quarter. Legendary investor Alexander Green has identified a backdoor ticker that gives regular investors access before an IPO announcement he expects no later than September 29. | The Oxford Club (Ad)Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsJune 11, 2026 | globenewswire.comEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryJune 5, 2026 | financialpost.comFEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury and Respiratory Distress at ERA CongressJune 5, 2026 | quiverquant.comQEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryJune 5, 2026 | globenewswire.comEDSA: Preparing for mid-2026 start to phase 2 vitiligo trialMay 22, 2026 | msn.comSee More Headlines EDSA Stock Analysis - Frequently Asked Questions How have EDSA shares performed this year? Edesa Biotech's stock was trading at $1.42 at the beginning of 2026. Since then, EDSA shares have increased by 324.6% and is now trading at $6.03. How were Edesa Biotech's earnings last quarter? Edesa Biotech, Inc. (NASDAQ:EDSA) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.25. When did Edesa Biotech's stock split? Edesa Biotech shares reverse split before market open on Wednesday, October 11th 2023.The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. How do I buy shares of Edesa Biotech? Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edesa Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edesa Biotech investors own include Pfizer (PFE), Ford Motor (F), Moderna (MRNA), Occidental Petroleum (OXY), Plug Power (PLUG), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings5/14/2026Today7/21/2026Next Earnings (Estimated)8/14/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 EDSA's financial health is in the Red zone, according to TradeSmith. EDSA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDSA CIK1540159 Webwww.edesabiotech.com Phone(289) 800-9600Fax805-488-2889Employees20Year Founded2015Price Target and Rating Average Price Target for Edesa Biotech$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside-17.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-286.52% Return on Assets-75.36% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book13.40Miscellaneous Outstanding Shares9,633,000Free Float7,283,000Market Cap$58.09 million OptionableNot Optionable Beta1.03 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:EDSA) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
